Filing Details

Accession Number:
0000899243-23-012167
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-03 20:28:19
Reporting Period:
2023-04-18
Accepted Time:
2023-05-03 20:28:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1744659 Akero Therapeutics Inc. AKRO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1778307 Andrew Cheng C/O Akero Therapeutics, Inc.
601 Gateway Boulevard, Suite 350
South San Francisco CA 94080
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-04-18 40,000 $0.62 409,293 No 4 M Direct
Common Stock Acquisiton 2023-05-01 25,000 $0.62 434,293 No 4 M Direct
Common Stock Disposition 2023-05-01 21,523 $45.00 412,770 No 4 S Direct
Common Stock Disposition 2023-05-01 3,477 $45.50 409,293 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-04-18 40,000 $0.00 40,000 $0.62
Common Stock Stock Option (Right to Buy) Disposition 2023-05-01 25,000 $0.00 25,000 $0.62
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
157,212 2028-09-07 No 4 M Direct
85,868 2028-10-17 No 4 M Direct
Footnotes
  1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person.
  2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.41 to $45.40, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
  3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.41 to $45.73, inclusive.
  4. The options are vested and currently exercisable.